Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Conditions

• Relapsed or Refractory DLBCL

Eligibility Criteria

Sex

ALL

Age

60 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Anti-PD-1 Antibody Plus Chidamide and Rituximab — DRUG
  Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks

Study Details

To assess the efficacy and safety of Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in the Treatment of Relapsed or Refractory DLBCL

Key Dates

Start date

Jun 1, 2022

Status verified

Apr 2022

Primary completion

Dec 31, 2022

Completion

Dec 31, 2024

Study Design

Enrollment

27 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL
  Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL

Primary Outcome Measure

complete response rate [ Time Frame: 24 weeks ]

Central Contacts

• Huiqiang Huang, professor
  0086-13808885154
  [email protected]